Collegium Pharmaceutical (NASDAQ:COLL) Share Price Breaks Above 50-Day Moving Average - Here's Why

Key Points

• Collegium Pharmaceutical shares rose 3.4%, trading at $24.03 after breaking above their 50-day moving average of $23.37, though they remained below the 200-day average of $33.48.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $48.71; targets range from $43 to $50, although some firms recently lowered estimates and one downgraded the stock to sell.
• The company’s latest quarterly results exceeded expectations, with EPS of $1.92 versus $1.72 expected and revenue of $199.88 million; revenue increased 6.3% year over year.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) crossed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $23.37 and traded as high as $24.18. Collegium Pharmaceutical shares last traded at $24.03, with a volume of 656,444 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on COLL shares. Oppenheimer began coverage on shares of Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 price objective for the company. Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating on the stock in a report on Wednesday, August 19th. Piper Sandler restated a "neutral" rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. Weiss Ratings cut shares of Collegium Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, September 4th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $48.71.

Collegium Pharmaceutical Trading Up 3.4%

The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The stock has a 50-day simple moving average of $23.37 and a two-hundred day simple moving average of $33.48. The firm has a market capitalization of $782.32 million, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 0.72 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analysts' expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.68 EPS. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of COLL. PNC Financial Services Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 418 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $36,000. Assetmark Inc. lifted its holdings in shares of Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company's stock worth $130,000 after purchasing an additional 335 shares during the period. Allworth Financial LP acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $175,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 20.6% during the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company's stock worth $167,000 after purchasing an additional 861 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.